HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions

Table 2

Broadly neutralizing antibodies, target sites, and breadth of neutralization.

Broadly neutralizing antibodies	Target site	Breadth of neutralization; (IC50 < 50 μg/mL)	Study
VRC01	CD4 binding site	89% of 180 isolates	Huang et al. (2012) [32]
VRC02	CD4 binding site	91% of 190 isolates	Wu et al. (2010) [33]
VRC03	CD4 binding site	57% of 190 isolates	Wu et al. (2010) [33]
VRC-PGV04	CD4 binding site	88% of 162 isolates	Walker et al. (2011) [34]
VRC-PGV04b	CD4 binding site	71% of 178 isolates	Wu et al. (2011) [35]
CH103	CD4 binding site	55% of 196 isolates	Liao et al. (2013) [22]
2F5	gp41	39% of 92 isolates	Corti et al. (2010) [36]
2G12	gp120	41% of 90 isolates	Binley et al. (2004) [37]
4E10	gp41	98% of 162 isolates	Walker et al. (2009) [38]
PG9	V1-V2 loops	78% of 180 isolates	Huang et al. (2012) [32]
PGT130	V3 loop	52% of 162 isolates	Walker et al. (2011) [34]
PGT151	gp120-gp41	66% of 117 cross-clade isolates	Bonsignori et al. (2014) [39]
PGT152	gp120-gp41	64% of 117 cross-clade isolates	Blattner et al. (2014) [40]

Source: http://www.hiv.lanl.gov/.